GB9827279D0 - Treatment of coronary and peripheral ischemia using an antithrombotic agent and an angiogenesis promoter - Google Patents
Treatment of coronary and peripheral ischemia using an antithrombotic agent and an angiogenesis promoterInfo
- Publication number
- GB9827279D0 GB9827279D0 GBGB9827279.2A GB9827279A GB9827279D0 GB 9827279 D0 GB9827279 D0 GB 9827279D0 GB 9827279 A GB9827279 A GB 9827279A GB 9827279 D0 GB9827279 D0 GB 9827279D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- coronary
- angiogenesis
- antithrombotic agent
- angiogenesis promoter
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A method for treating a patient having coronary and/or peripheral ischemic syndrome by administering to the patient an effective amount of an antithrombotic agent, e.g. a glycoprotein IIb/IIIa antagonist, a thrombin inhibitor, a factor Xa inhibitor, or a low molecular weight heparin, and an effective amount of an angiogenesis promoter, e.g. a vascular endothelial growth factor or a fibroblast growth factor. Administration of the angiogenesis promoters may be by any suitable means known to persons skilled in the art, e.g. via bolus injection, continuous intravenous administration, coated stent implantation and gene transfer, which provides localized or systemic delivery of the angiogenesis promoter at the ischemic tissue.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6825797P | 1997-12-19 | 1997-12-19 | |
GBGB9806705.1A GB9806705D0 (en) | 1998-03-27 | 1998-03-27 | Treatment of coronary and peripheral ischemia using an antihrombotic agent and an angiogenesis promoter |
Publications (2)
Publication Number | Publication Date |
---|---|
GB9827279D0 true GB9827279D0 (en) | 1999-02-03 |
GB2332373A GB2332373A (en) | 1999-06-23 |
Family
ID=26313388
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB9827279A Withdrawn GB2332373A (en) | 1997-12-19 | 1998-12-11 | Treatment of coronary and/or peripheral ischemia using an antithrombotic agent and an angiogenesis promoter |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2332373A (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4643501A (en) * | 2000-02-04 | 2001-08-14 | Flanders Interuniversity Institute For Biotechnology (Vib) | Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke |
US7727971B2 (en) | 2000-02-04 | 2010-06-01 | Life Sciences Research Partners Vzw | Use of placental growth factor for treating ischemic muscle disease |
US6930089B2 (en) | 2000-02-04 | 2005-08-16 | D. Collen Research Foundation Vzw | Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic disease or stroke |
US7105168B1 (en) | 2002-06-04 | 2006-09-12 | D. Collen Research Foundation Vzw | Method of improving ischemic muscle function by administering placental growth factor |
AU5523701A (en) * | 2000-04-06 | 2001-10-23 | Wayne P Franco | Methods of using growth factors for treating heart disease |
GB0120690D0 (en) | 2001-08-24 | 2001-10-17 | Novartis Ag | Organic compounds |
AU2002363369B2 (en) * | 2001-10-15 | 2008-08-21 | Janssen Pharmaceutica N.V. | Substituted 4-phenyl-4-(1H-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage |
GB0414441D0 (en) * | 2004-06-28 | 2004-07-28 | Imp College Innovations Ltd | Improved anti-viral compositions |
DE602006017071D1 (en) * | 2005-01-25 | 2010-11-04 | Five Prime Therapeutics Inc | COMPOSITIONS AND METHODS OF TREATING HEART DISEASES |
WO2009132457A1 (en) * | 2008-05-02 | 2009-11-05 | University Of Western Ontario | Fgf-9 and its use relating to blood vessels |
CN105879130A (en) * | 2016-06-08 | 2016-08-24 | 刘厂辉 | Novel drug-coated stent |
EP3710043B1 (en) * | 2017-11-16 | 2024-04-17 | Universite d'Aix-Marseille | Fgf10 for the treatment of heart diseases |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997035615A1 (en) * | 1996-03-27 | 1997-10-02 | Merck & Co., Inc. | Compositions and methods for inhibiting clot formation |
-
1998
- 1998-12-11 GB GB9827279A patent/GB2332373A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
GB2332373A (en) | 1999-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB9827279D0 (en) | Treatment of coronary and peripheral ischemia using an antithrombotic agent and an angiogenesis promoter | |
Robson | The role of growth factors in the healing of chronic wounds | |
EP0565620B1 (en) | Mitotoxin for treatment of vascular injury | |
Harker et al. | Thrombin hypothesis of thrombus generation and vascular lesion formation | |
US6297219B1 (en) | Site-specific instillation of cells or site-specific transformation of cells and kits therefor | |
US6660034B1 (en) | Stent for increasing blood flow to ischemic tissues and a method of using the same | |
US8455453B2 (en) | Use of VEGF-D gene to prevent restenosis | |
CA2212537A1 (en) | Therapeutic inhibitor of vascular smooth muscle cells | |
Muller et al. | Colchicine and antineoplastic therapy for the prevention of restenosis after percutaneous coronary interventions | |
WO2001013031A3 (en) | Dose of an angiogenic factor and method of administering to improve myocardial blood flow | |
EP0852491A4 (en) | Use of heparinases to decrease inflammatory responses | |
Tanguay et al. | Prevention of in-stent restenosis via reduction of thrombo-inflammatory reactions with recombinant P-selectin glycoprotein ligand-1 | |
ATE485825T1 (en) | THERAPEUTIC INHIBITORS OF VASCULAR SMOOTH CELLS | |
JP7343305B2 (en) | Compositions and methods for immunomodulation by anti-LYST | |
Dosne et al. | Tumor necrosis factor (TNF) stimulates plasminogen activator inhibitor (PAI) production by endothelial cells and decreases blood fibrinolytic activity in the rat | |
Kleiman et al. | Evolving revascularization approaches for myocardial ischemia | |
Bartorelli et al. | Local heparin delivery prior to coronary stent implantation: acute and six‐month clinical and angiographic results | |
Atkinson | Ancrod in the treatment of acute ischaemic stroke | |
WO2002058720A3 (en) | Angiogenically effective unit dose of fgf-2 and method of use | |
ATE279937T1 (en) | FGF-2 ANGIOGENIC EFFECTIVE UNIT DOSE AND ITS USE | |
Kagan et al. | Mediators of restenosis | |
Häyry et al. | Blockade of growth factor synthesis and growth factor action: two possible sites of interference in allograft vessel disease and coronary bypass or balloon injury | |
US20020034505A1 (en) | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor | |
JPH09151137A (en) | Medicine for inhibiting multiplication of smooth muscle cell | |
Nugent et al. | Local drug delivery and tissue engineering regulate vascular injury |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |